TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05733299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: aflo™ digital respiratory management platform
Description: medical device, user app, clinician portal, data analytics hub

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Health service standard care will be continued

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Health service standard care will be continued
Study: NCT06398405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epigallocatechin-3-gallate
Description: Epigallocatechin-3-gallate is administered in a solution with a concentration of 4400 umol/L
Study: NCT06464159

Intervention type: BIOLOGICAL
Intervention: Biological collection
Description: A collection of maternal plasma, serum and urine

Intervention type: BIOLOGICAL
Intervention: Biological collection
Description: A collection of maternal plasma, serum and urine

Intervention type: BIOLOGICAL
Intervention: Biological collection
Description: A collection of maternal plasma, serum and urine
Study: NCT06281613

Intervention type: DEVICE
Intervention: AMCOP group
Description: Patients were treated with AMCOP for 18 months.

Intervention type: DEVICE
Intervention: High-pull headgear
Description: Patients were treated with high-pull headgear for 18 months.
Study: NCT05573412

Intervention type: OTHER
Intervention: Cellular analysis
Description: Previously cryopreserved samples will be analyzed for total nucleated cell count (TNC), cell viability and proliferative potential
Study: NCT04764266

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Heparansulfate and Syndecan 1
Description: Blood samples will be collected from the patient at 5 different time points. Three perfusate samples will be collected during normothermic machine perfusion (4,9ml each).
Study: NCT06403475

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagus Nerve Stimulation
Description: Transcutaneous auricular vagus nerve stimulation using the Nurosym (Parasym Ltd) device.~Stimulation parameters:~Pulse width: 250µs; Frequency: 25Hz; Intensity: Below pain threshold.~The active stimulation will be delivered to the left tragus. Participants will complete the intervention at home once they have received sufficient training on how to use the stimulation device.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous Vagus Nerve Stimulation
Description: Stimulation will be delivered at the same parameters however, sham stimulation will be delivered to the left earlobe. Earlobe stimulation has been used as a sham in other studies as it is not thought to activate the vagus nerve.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Computer Based Speech and Language Therapy (Step by Step)
Description: Computer-based Speech and Language Therapy will be completed whilst wearing the stimulation device in all groups. The Step by Step programme uses an errorless learning approach to practice naming. All participants will practice a set of 30 meaningful words during the intervention. Participants will complete the SLT programme at home on an ipad, whilst using the stimulation device.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer Based Speech and Language Therapy (Step by Step)
Description: Computer-based Speech and Language Therapy will be completed whilst wearing the stimulation device in all groups. The Step by Step programme uses an errorless learning approach to practice naming. All participants will practice a set of 30 meaningful words during the intervention. Participants will complete the SLT programme at home on an ipad, whilst using the stimulation device.
Study: NCT05662566

Intervention type: PROCEDURE
Intervention: Epidural replacement
Description: Insufficient analgesic effect of epidural anesthesia to the extent were replacement of the catheter is needed.~Defined as insertion of a new epidural catheter

Intervention type: PROCEDURE
Intervention: Epidural replacement
Description: Insufficient analgesic effect of epidural anesthesia to the extent were replacement of the catheter is needed.~Defined as insertion of a new epidural catheter
Study: NCT05697978

Intervention type: DEVICE
Group type: OTHER
Intervention: Monofocal intraocular lens Clareon (Alcon LLC)
Description: monofocal aspheric lens implanted in eyes of patient during routine cataract surgery
Study: NCT04980326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doing What Matters (DWM)
Description: The original DWM program consists of a self-help guide called 'Doing What Matters in Times of Stress', that is complemented with pre-recorded audio exercises. The audio material imparts key information about stress management and guides participants through individual exercises. Additionally, participants are guided by a briefly trained helper. In this study, DWM will be delivered as an online intervention. The DWM intervention, i.e. both the audio recordings and the self-help guide, will be adapted for use on a smartphone or other device with internet access during Phase 1 of RESPOND. The format of DWM is innovative in that it seeks to ensure that key intervention components are delivered as intended through the use of pre-recorded audio, without the burden of extensive training and supervision. In the online application tool a new module is released every week so participants will be asked to go through the entire DWM intervention within 5 weeks with weekly guidance from a helper.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Management Plus (PM+)
Description: PM+ is a new, brief, psychological intervention program based on cognitive behavioral therapy (CBT) techniques. The manual involves the following empirically supported elements: problem solving plus stress management, behavioral activation, facing fears, and accessing social support. Across the five 90-minute sessions participants may talk to trained non-professional. PM+ has four core features, and it is brief. In this study, the delivery mode of the PM+ intervention will be flexible, with remote delivery in phases of the pandemic when physical distancing rules apply. This is a future-oriented attempt towards a more holistic mental health care system that can flexibly switch between modes of delivery (e.g. remotely (e.g. Zoom) or face-to), depending on the needs and the specific containment measures that apply, and the specific preferences and needs of the participant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychological First Aid (PFA)
Description: PFA is a brief intervention consisting of providing basic information for peer support in times of emotional distress

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological First Aid (PFA)
Description: PFA is a brief intervention consisting of providing basic information for peer support in times of emotional distress
Study: NCT06409455

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive Dementia Caregiving in 30 Days
Description: Based on an evidence-based face-to-face Benefit-Finding Intervention, a computer-delivered web-based program supporting 24/7 access without location restriction, is developed. It is a psychoeducation program with an emphasis on strengthening caregivers' coping capacity through skills training and developing a positive way of looking at caregiving challenges. The program consists of reading materials, illustrated texts, caregivers' testimonies, a chatbot, and several interactive apps to facilitate self-learning at the caregiver's own pace.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Positive Dementia Caregiving in 30 Days
Description: Based on an evidence-based face-to-face Benefit-Finding Intervention, a computer-delivered web-based program supporting 24/7 access without location restriction, is developed. It is a psychoeducation program with an emphasis on strengthening caregivers' coping capacity through skills training and developing a positive way of looking at caregiving challenges. The program consists of reading materials, illustrated texts, caregivers' testimonies, a chatbot, and several interactive apps to facilitate self-learning at the caregiver's own pace.
Study: NCT04907851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXC004
Description: RXC004 will be administered orally, 2 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXC004
Description: RXC004 will be administered orally, 2 mg QD (Cohort 1, Module 2) and 1 mg QD (Cohort 2, Module 2); Dose Formulation: 0.5 mg or 1 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXC004
Description: RXC004 will be administered orally, 1.5 mg QD; Dose Formulation: 0.5 mg or 1 mg capsules.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month; Use: Prophylactic

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month; Use: Prophylactic

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month; Use: Prophylactic

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Pembrolizumab will be administered via intravenous infusion, 400 mg dose once every 6 weeks
Study: NCT06073990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia (BBTi)
Description: The intervention consists of four weeks of BBTi. During the first week, participants will receive face-to-face sleep assessments and sleep hygiene education. In the second week, a phone interview will be conducted to assess the patient's progress and provide appropriate relaxation techniques. Unsatisfactory responses to sleep restriction therapy or stimulation control methods will be addressed through face-to-face interviews in the third week. The fourth week will involve an overall review and evaluation conducted via a telephone interview.
Study: NCT06022484

Intervention type: OTHER
Intervention: The present study does not contain any intervention
Description: The present study does not contain any intervention

Intervention type: OTHER
Intervention: The present study does not contain any intervention
Description: The present study does not contain any intervention
Study: NCT06520969

Intervention type: OTHER
Group type: OTHER
Intervention: Prevelance of Uterine Vein and Uterine Vein System Variations (anatomical study)
Description: Single arm anatomical study describing the prevalance and anatomical variations of superficial and deep veins in endometrial and cervical cancer patients
Study: NCT06172894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APN401
Description: APN401 is a suspension of viable peripheral blood mononuclear cells (PBMCs) from an individual patient that have been transfected with a small interfering ribonucleic acid (siRNA) to reduce Cbl-b expression. It is administered intravenously in 3-weekly intervals (i.e. every 21 days) for a maximum of 4 treatment cycles.
Study: NCT05396963

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Egg white
Description: Intake of egg white

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Egg white
Description: Intake of egg white

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Egg white
Description: Intake of egg white

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Egg white
Description: Intake of egg white

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Egg white
Description: Intake of egg white

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Egg white
Description: Intake of egg white

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Whey protein
Description: Intake of whey protein
Study: NCT05736263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise
Description: moderate intensity aerobic exercise trial

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval exercise
Description: High intensity interval exercise trial

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined exercise
Description: Combined aerobic and resistance exercise trial
Study: NCT05396963

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Whey protein
Description: Intake of whey protein

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Whey protein
Description: Intake of whey protein

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Whey protein
Description: Intake of whey protein

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Whey protein
Description: Intake of whey protein

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Whey protein
Description: Intake of whey protein

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Maltodextrin
Description: Intake of maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Maltodextrin
Description: Intake of maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Maltodextrin
Description: Intake of maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Maltodextrin
Description: Intake of maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Maltodextrin
Description: Intake of maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Maltodextrin
Description: Intake of maltodextrin
Study: NCT05736263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Resistance exercise trial
Study: NCT05951192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daprodustat
Description: Commercially manufactured daprodustat (JESDUVROQ) is provided in tablet strengths of 1, 2, 4, 6 and 8 mg. Tablets will be taken whole and patients will be instructed not to cut, crush, or chew tablets.
Study: NCT05882578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oncological physical exercise intervention
Description: An initial physical assestment where clinical history, body composition, functionality, cardiovascular fitness and quality of life will be tested.~Patients will be screened and then divided in diferent groups, depending on both their cardiovascular and physical capacity.~Then they will perform 2 sessions of combined strength and endurance training per week for 16 weeks.~At the end of the training program, the patients will be assesed to evaluate the changes in their cardiovascular fitness, functionality, body composition and quality of life.
Study: NCT05326386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HTN and Medication Adherence
Description: Via the Way to Health platform, all patients will receive daily text messages asking about medication adherence for that day and twice weekly text messages asking if participants have measured blood pressure on that day.~Participants are entered into a game. Each week they receive 90 points. If they took their medications or checked their blood pressure the prior day, they keep their points, but if not, they lose 10 points. At the end of the week if they have at least 70 points they move up a level, but if not, they drop a level. Participants start in the middle of 5 levels.~Participants choose a support partner. At the start of the intervention, the study team holds a 3-way phone call with the participant and support partner to discuss ways they can help the participant meet their goal. The support partner gets a weekly email with the participant's progress.~Primary care physicians will receive a monthly email noting patients' self-reported adherence and blood pressure.
Study: NCT05538416

Intervention type: PROCEDURE
Intervention: Posterior Lumbar Interbody Fusion (PLIF)
Description: Spinal fusion in the lumbar spine by inserting a cage directly into the disc space. This is an observational study in which the standard procedure/care is followed.

Intervention type: PROCEDURE
Intervention: Posterior Lumbar Interbody Fusion (PLIF)
Description: Spinal fusion in the lumbar spine by inserting a cage directly into the disc space. This is an observational study in which the standard procedure/care is followed.

Intervention type: PROCEDURE
Intervention: Posterior Lumbar Interbody Fusion (PLIF)
Description: Spinal fusion in the lumbar spine by inserting a cage directly into the disc space. This is an observational study in which the standard procedure/care is followed.
Study: NCT05882578

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Physical Activities intervention
Description: An initial physical assestment where clinical history, body composition, functionality, cardiovascular fitness and quality of life will be tested Patients will be suggested to mantain active physical activities in their daily life.~At the end of the training program, the patients will be assesed to evaluate the changes in their cardiovascular fitness, functionality, body composition and quality of life.
Study: NCT05916352

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine Supplement
Description: Caffeine tablet

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine Supplement
Description: Caffeine tablet
Study: NCT04141371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Molar Sodium Lactate
Description: daily 3-hour infusion of sodium molar lactate during the vasospasm period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: physiological serum
Description: daily saline infusion over 3 hours during the vasospasm period
Study: NCT04814264

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Red blood cells
Description: All transfused red blood cells will be obtained from Canadian Blood Services and will be the standard red blood cell products currently provided in Canada.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Red blood cells
Description: All transfused red blood cells will be obtained from Canadian Blood Services and will be the standard red blood cell products currently provided in Canada.
Study: NCT05428709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acute Exercise
Description: Participants will be asked to walk or jog on a treadmill for a maximal exercise test.
Study: NCT05376319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 1000 mg per infusion given approximately two weeks apart, on day 1 and on day 15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: 1000 mg per infusion given approximately two weeks apart, on day 1 and on day 15
Study: NCT05170594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at 15mg/kg IV, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered at 15mg/kg IV, every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: The non-platinum chemotherapy regimen will be determined by the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: The non-platinum chemotherapy regimen will be determined by the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib
Description: Fluzoparib will be administered orally continuously at 150mg bid until disease progression and toxicity becomes intolerable
Study: NCT04815759

Intervention type: OTHER
Intervention: routine dental restorative procedures
Description: pulp and restorative therapy

Intervention type: OTHER
Intervention: routine dental restorative procedures
Description: pulp and restorative therapy
Study: NCT04857008

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BNT001
Description: BNT001 is a commercially-available, prescription-only, software / medical device in the form of a digital application (digital app) for use on the participant's mobile device which delivers 10-sessions on cognitive behavioral therapy for cancer patients.
Study: NCT05665205

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic plus strength group
Description: A 8 week program of aerobic exercise plus strength exercise of upper and lower limbs in the hospital with a supervised trained physiotherapist

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Aerobic group
Description: This group has a 8 weeks program of only aerobic exercise in the hospital with a supervised trained physiotherapist.
Study: NCT05379647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QN-019a
Description: Experimental Interventional Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QN-019a
Description: Experimental Interventional Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid
Description: Lympho-conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid
Description: Lympho-conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP-16
Description: Lympho-conditioning Agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP-16
Description: Lympho-conditioning Agent
Study: NCT06265298

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conjunctival reconstruction
Description: Conjunctival reconstruction using buccal mucosa taken from the patient's mouth. Following the reconstruction operation, an additional biopsy of buccal mucosa will be taken to develop a laboratory protocol for the transdifferentiation of these buccal cells into corneal epithelial stem cells.
Study: NCT05598268

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011
Description: T3011 will be administered through IV drip
Study: NCT04448301

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PointCheck
Description: This is a usability study on PointCheck, a new technology to detect chemotherapy-induced neutropenia
Study: NCT06565650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miebo
Description: 100% perfluorohexyloctane

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.6% sodium chloride solution
Study: NCT05339074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: 60 patients will receive ketamine hydrochloride over 12 weeks, flexible dosed between 0.5 mg/kg to 1.0 mg/kg
Study: NCT05486728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHJ002/Vehicle
Description: Topical ophthalmic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHJ002/Vehicle
Description: Topical ophthalmic